Varsano I, Eidlitz-Marcus T, Nussinovitch M, Elian I
Department of Pediatrics and Microbiology, Tel Aviv University School of Medicine, Hasharon Hospital, Petah Tiqva, Israel.
J Pediatr. 1991 Apr;118(4 Pt 1):627-32. doi: 10.1016/s0022-3476(05)83392-x.
In a prospective randomized open study, ceftriaxone, 50 mg/kg per day, was compared with ampicillin, 100 mg/kg per day, both given for a period of 5 days, for the treatment of 40 children whose mean (+/- SD) age was 4.5 +/- 3.2 years and who had severe dysentery caused by Shigella organisms. Twenty patients were treated with ceftriaxone and 20 with ampicillin. Both drugs were initially given intravenously for a period of 1 to 2 days and were continued intramuscularly, in the case of ceftriaxone, or orally, in the patients receiving ampicillin. All Shigella organisms isolated were susceptible to ceftriaxone; 28% were resistant to ampicillin. The diarrhea persisted for a mean (+/- SD) period of 2.5 +/- 1.0 days in the ceftriaxone-treated patients versus 6.8 +/- 6.3 days in the ampicillin-treated patients (p less than 0.005). At the end of the 5 days of therapy, stool cultures for Shigella organisms were negative in 12 (60%) of the 20 patients from the ampicillin group and in all the children (100%) from the ceftriaxone group (p less than 0.001). Bacteriologic relapses were observed in eight (40%) of the patients treated with ampicillin but in none of the children treated with ceftriaxone (p less than 0.001). In instances of clinical or bacteriologic failure in the ampicillin group, retreatment was instituted in most of the cases with ceftriaxone; persistent clearing of the Shigella organisms from the stool was finally achieved after a mean (+/- SD) period of 11.75 +/- 9.4 days after therapy was started, as compared with 1.85 +/- 0.6 days in the ceftriaxone-treated patients (p less than 0.001). We conclude that in children with severe shigellosis, treatment with ceftriaxone for 5 days is effective and better than use of ampicillin for clinical cure and eradication of the Shigella organisms from the stool.
在一项前瞻性随机开放研究中,将每天50mg/kg的头孢曲松与每天100mg/kg的氨苄西林进行比较,两者均给药5天,用于治疗40名平均(±标准差)年龄为4.5±3.2岁、由志贺菌属引起严重痢疾的儿童。20名患者接受头孢曲松治疗,20名接受氨苄西林治疗。两种药物最初均静脉给药1至2天,头孢曲松随后继续肌肉注射,接受氨苄西林治疗的患者则改为口服。所有分离出的志贺菌属对头孢曲松均敏感;28%对氨苄西林耐药。头孢曲松治疗组患者腹泻持续的平均(±标准差)时间为2.5±1.0天,而氨苄西林治疗组为6.8±6.3天(p<0.005)。治疗5天后,氨苄西林组20名患者中有12名(60%)志贺菌属粪便培养转阴,头孢曲松组所有儿童(100%)均转阴(p<0.001)。接受氨苄西林治疗的患者中有8名(40%)出现细菌学复发,而接受头孢曲松治疗的儿童无一例复发(p<0.001)。在氨苄西林组出现临床或细菌学治疗失败的情况下,大多数病例改用头孢曲松重新治疗;开始治疗后,平均(±标准差)11.75±9.4天粪便中志贺菌属最终持续清除,而头孢曲松治疗组患者为1.85±0.6天(p<0.001)。我们得出结论,对于患有严重志贺菌病的儿童,头孢曲松治疗5天有效,且在临床治愈和清除粪便中志贺菌属方面优于氨苄西林。